Rexin G is a tumor-targeted gene therapy that uses a retrovector carrying a cytocidal cyclin G1 construct to deliver a therapeutic gene directly into cancer cells. It has been studied against multiple solid tumors, with notable effectiveness reported in chemotherapy-resistant pancreatic cancer, where it was associated with tripled survival times in clinical studies. Rexin G received regulatory approval from the Philippine Food and Drug Administration in 2007 for the treatment of all solid tumors, and it holds an orphan drug designation in the United States, where it completed phase one and two trials and advanced toward phase three trials by 2011. Studies describe it as showing significant anti-tumor activity and increasing both overall survival time and survival rates in most treated patients.
Facts
Drug ClassTumor-targeted replication-incompetent retroviral vector (gene therapy) encoding a dominant-negative cyclin G1 construct 3 Mechanism of ActionDelivers a dominant-negative human cyclin G1 construct to tumors by a retroviral vector that targets abnormal Signature (SIG) proteins 3 First Approved / Isolated Year Classification
Approval StatusInvestigational / Clinical Trial 1 ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration Connections
Sources
1. Rexin-G (Wikipedia)
lead sentence 3
After phase one and two clinical trials, the drug has been shown to effectively shrink metastatic tumors and triple the survival times of chemotherapy-resistant pancreatic cancers.
- Route of administration
View the Source2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer (Molecular Therapy Oncolytics, 2018)
Abstract, definition sentence
Rexin-G is a replication-incompetent retroviral vector displaying a cryptic SIG-binding peptide for targeting abnormal Signature (SIG) proteins in tumors and encoding a dominant-negative human cyclin G1 construct.
Abstract, targeting and construct description
Rexin-G is a replication-incompetent retroviral vector displaying a cryptic SIG-binding peptide for targeting abnormal Signature (SIG) proteins in tumors and encoding a dominant-negative human cyclin G1 construct.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.